Enoxaparin
| dc.contributor.author | Padayachee, N. | |
| dc.contributor.author | Schoeman, N. | |
| dc.contributor.author | Schellack, Natalie | |
| dc.date.accessioned | 2022-07-29T06:55:25Z | |
| dc.date.available | 2022-07-29T06:55:25Z | |
| dc.date.issued | 2021-05 | |
| dc.description.abstract | The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality. | en_US |
| dc.description.department | Pharmacology | en_US |
| dc.description.uri | http://www.sapj.co.za | en_US |
| dc.identifier.citation | Padayachee N., Schoeman N. & Schellack, N. 2021, 'Enoxaparin', SA Pharmaceutical Journal, vol. 88, no. 2, pp. 26-29, doi : 10.10520/ejc-mp_sapj_v88_n2_a7. | en_US |
| dc.identifier.issn | 2221-5875 (print) | |
| dc.identifier.issn | 2220-1017 (online) | |
| dc.identifier.other | 10.10520/ejc-mp_sapj_v88_n2_a7 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/86582 | |
| dc.language.iso | en | en_US |
| dc.publisher | Medpharm Publications | en_US |
| dc.rights | Medpharm Publications. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. | en_US |
| dc.subject | Enoxaparin | en_US |
| dc.subject | Coagulopathy | en_US |
| dc.subject | Factor Xa | en_US |
| dc.subject | Low-molecular weight heparin (LMWH) | en_US |
| dc.subject | COVID-19 pandemic | en_US |
| dc.subject | Coronavirus disease 2019 (COVID-19) | en_US |
| dc.subject | Thrombotic conditions | en_US |
| dc.title | Enoxaparin | en_US |
| dc.type | Article | en_US |